LyonHeart fills need for creative head

Share this article:
Hébert: entrepreneurial
Hébert: entrepreneurial

New York-based LyonHeart hired Steven Hébert to lead its creative department, the agency said.

LyonHeart, which is part of Diversified Agency Services (DAS), the marketing services network of holding company Omnicom Group, said Hébert will oversee all creative work, including two associate creative directors, and will report directly to Anne Devereux, chairman and CEO.

“As our clients walk the fine line between building strong brands and managing the scrutiny of today's environment, we needed to find talent who could help us transform the agency to maximize our effectiveness despite the hurdles,” Devereux said in a statement announcing the hire.

Part of that transformation involves lending creative talent a stronger voice, as well as bringing in those with digital experience as the agency becomes increasingly engaged in interactive projects. Devereaux, who assumed day-to-day management of the 175-person agency more than a year ago after the departure of former CEO Susan Flinn, cited Hébert's “blend of entrepreneurial creativity and respect for the industry.”

Hébert joins LyonHeart from The CementBloc, a group of four agencies. In 2008 he launched its StoneWorks division, helping the unit win new business in the areas of hemophilia, devices, neurology, transplants and aesthetics. Overall CementBloc revenues grew 78% to $36.2 million in 2008. Hebert's previous work includes creative roles at Sudler & Hennessey and Grey Healthcare Group.

LyonHeart, which until 2007 was known as Lyons Lavey Nickel Swift, offers advertising and promotion as well as CME programs. Its biggest clients include Pfizer, Merck and Roche, all of which have been involved in mergers this past year. Its other clients include UCB, Otsuka, Jazz, Daiichi-Sankyo, Johnson & Johnson and Forest.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...